Fierce Biotech has released its long-awaited list of the 25 most influential people in the biopharma field. The inventory has a good European presence with professionals that are revolutionizing the industry.
Hans Bishop, from Juno Therapeutics. The CEO of the American rising star in the biotech industry was born and raised in UK. The company, he co-founded is expanding, as the recent acquisition of the German biotech Stage Cell Therapeutics shows.
Emmanuelle Charpentier, from CRISPR Therapeutics. The laureate French scientist and the other side of the CRISPR coin, Jennifer Doudna, are both in this list, thanks to their groundbreaking work on a gene-editing tool.
David Epstein, from Novartis. This member of the Executive Committee of Novartis has lead the company’s Oncology business from its very beginning as a mere start-up, to ranking second worldwide due to six new drug approvals and more than 10 indication expansions, as he was Head of Novartis Oncology.
George Freeman, from U.K. Parliament. The British politician from the Conservative Party is a fervent defender of UK’s potential in science, technology and entrepreneurship.
Brent Saunders, from Actavis. The CEO of the global pharma, headquartered in Dublin, is putting the company on the right path. Actavis just reported an exceptional performance in the first quarter of the current year.
Serge Weinberg, from Sanofi. Since 2010, Weinberg is the Chairman of the Board of Director of the French company. His leadership has enabled Sanofi’ succesful pivot from Chemistry to Biotechnology.
Neil Woodford, from Patient Capital Trust. The English economist has been starring in some of our latest news thanks to his key investments in the biotech field, some of which destined to PsiOxus or Kymab.
The selection of these prominent professionals, in addition to the latest victories in the stockmarkets, is yet another symptom of the great momentum of the European biotech industry.